Ask about this productRelated genes to: RANTES antibody
- Gene:
- CCL5 NIH gene
- Name:
- C-C motif chemokine ligand 5
- Previous symbol:
- D17S136E, SCYA5
- Synonyms:
- RANTES, SISd, TCP228, MGC17164
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 1990-07-05
- Date modifiied:
- 2016-03-01
Related products to: RANTES antibody
Related articles to: RANTES antibody
- Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, characterized by a highly immunosuppressive tumor microenvironment (TME) that facilitates immune evasion and tumor progression. - Source: PubMed
Publication date: 2026/04/15
Bian YiboHuangfu ChaonanLu Yuanyuan - Piroplasmosis, including Theileriosis and Babesiosis, poses a threat to livestock health and productivity worldwide. However, the molecular mechanisms underlying breed-specific differences in resistance to piroplasmosis remain poorly understood. Compared to Bos taurus, Bos indicus generally exhibits greater resistance to diseases such as piroplasmosis and trypanosomiasis, as well as enhanced adaptability to hot and humid environments. Yunnan humped cattle, an indigenous B. indicus breed, are well adapted to coarse feed and harsh environments, yet the molecular basis of their disease resistance has not been systematically investigated. - Source: PubMed
Publication date: 2026/04/30
Chen YumingChen XiaonaLiu RongLi ChunqingXiao HengChen Shanyuan - Acquired resistance to Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, remains a major therapeutic challenge in EGFR-mutant non-small cell lung cancer (NSCLC). Here, we report that cepharanthine (CEP), a natural bisbenzylisoquinoline alkaloid, effectively reverses gefitinib resistance through concurrent suppression of the AKT/P70S6K survival axis and activation of the Stimulator of Interferon Genes (STING)-mediated innate immune pathway. In gefitinib-resistant H1975 cells (EGFR L858R/T790M), CEP monotherapy significantly inhibited proliferation and induced mitochondrial apoptosis. Notably, CEP synergized with gefitinib to enhance therapeutic efficacy. RNA sequencing and functional validation revealed that CEP activates the STING/TANK-Binding Kinase 1 (TBK1)/Interferon Regulatory Factor 3 (IRF3) signaling cascade, resulting in robust production of T-cell chemoattractants C-X-C Motif Chemokine Ligand 9 (CXCL9), C-X-C Motif Chemokine Ligand 10 (CXCL10), and C-C Motif Chemokine Ligand 5 (CCL5). Critically, the STING inhibitor H-151 abolished CEP's antitumor effects in vitro. Our findings reveal a novel dual mechanism action of CEP and nominate it as a potential candidate for overcoming TKI resistance in NSCLC. - Source: PubMed
Kang Li-PingChen Hui-HuiLv Tong-TongHuang Hua-JingHuang Dong-HuiChen Ying-QingJiang Ze-Bo - Botanical ingredients can function as adjunctive therapies for managing inflammatory skin diseases. - Source: PubMed
Ha DanbeeJung KyungsookChoi HyungyeongYoon Ji-Seon - Oligoarticular juvenile idiopathic arthritis (oligo JIA) is the most common JIA subtype and is often complicated by uveitis, a potentially sight-threatening comorbidity. Despite its prevalence, the immunopathogenic mechanisms underlying oligo JIA and its extra-articular manifestations remain poorly understood. The objective was to characterize the immune landscape of oligo JIA and identify pathogenic cell populations and regulatory mechanisms associated with the disease and uveitis. - Source: PubMed
Publication date: 2026/04/27
Lopez-Corbeto MireiaGuillén YolandaJiménez-Gracia LauraMoreno-Ruzafa EstefaníaAlvarez-Errico DamianaPalau NúriaMartín-Begué NievesHeyn HolgerJulià AntonioMarsal Sara